Chronic antibiotic suppression of cystic fibrosis (CF) infections has increased in the United States, as has isolation of Pseudomonas aeruginosa with reduced antibiotic susceptibility. However, analysis of the susceptibilities of 193 initial P aeruginosa clinical isolates suggests that antibiotic susceptibilities are comparable with wild-type strains despite expanded antipseudomonal treatment in the CF community.
Chronic Pseudomonas aeruginosa airway infection has been associated with accelerated lung disease progression and decreased survival in cystic fibrosis (CF). This finding has led clinicians (1) to the practice of aggressively treating new P aeruginosa airway infections with antibiotics in an attempt to convert patients to culture-negativity [1] and (2) to the practice of chronic antibiotic use for suppression of established P aeruginosa infections [2] . Although the long-term clinical benefit of delaying establishment of chronic P aeruginosa infection remains largely theoretical [1] , chronic use of antibiotics to suppress established P aeruginosa infection has been shown to provide a sustained improvement in lung function and to reduce risk of pulmonary exacerbation [2] . However, it is not known whether the resulting increased presence of multiple antibiotic-resistant P aeruginosa among chronically infected patients [3, 4] has resulted in the isolation of new P aeruginosa with multiple antibiotic resistance in children with CF.
We have examined the in vitro antibiotic susceptibility of P aeruginosa isolates recovered from children with CF at baseline in a randomized trial of antibiotic treatments for initial P aeruginosa airway infections [5] to quantify the prevalence of in vitro antibiotic resistance among new isolates, because this may indicate lateral transmission of P aeruginosa from individuals with chronic P aeruginosa airway infection.
METHODS
In vitro antibiotic susceptibility was determined for P aeruginosa recovered from children with CF ranging from 1 to 12 years of age at entry into the Early Pseudomonas Infection Control (EPIC) clinical trial [5] . Newly acquired P aeruginosa was defined as either the first documented P aeruginosa isolation or isolation after 2 years of culture negativity. For children ages 12 to 15 months, at least 1 isolation of P aeruginosa since birth was required. Other eligibility criteria have been previously reported [5] . All participating study sites obtained institutional review board approval, and parents or guardians provided informed consent.
Respiratory tract secretions collected by throat swab were cultured, and P aeruginosa isolates were tested at the Center for CF Microbiology at Seattle Children's Hospital (Seattle, Washington) as previously described [5] . If morphologically distinct P aeruginosa colonies were identified within a subject's specimen, susceptibility of each morphotype was determined separately. In vitro minimum inhibitory concentrations (MICs) were determined using microdilution methods for 9 antipseudomonal antibiotics: amikacin, aztreonam, ciprofloxacin, cefepime, ceftazidime, meropenem, pipericillin/tazobactam, ticarcillin/clavulanate, and tobramycin. Minimum inhibitory concentrations inhibiting the in vitro growth of 50% and 90% of the isolate population (MIC 50 and MIC 90 ) were calculated. Isolate MICs were compared with published interpretive P aeruginosa susceptibility criteria to identify isolates with MICs exceeding parenteral breakpoints as defined by the Clinical Laboratory Standards Institute and therefore considered to be associated with a higher likelihood of treatment failure [6] . Antibiotic susceptibilities of EPIC isolates were compared with those of wild-type P aeruginosa strains [7] .
RESULTS
One hundred ninety-three P aeruginosa isolates were recovered from throat swabs of 117 participants who were culturepositive for P aeruginosa at their baseline visit, with 67 participants (57.3%) contributing 1 isolate, 33 participants (28.2%) contributing 2 isolates, 10 participants (8.5%) contributing 3 isolates, 5 participants (4.3%) contributing 4 isolates, and 2 participants (1.7%) contributing 5 isolates. In all, 58 of 1737 individual antibiotic susceptibility tests (3.3%) yielded an MIC above published parenteral breakpoints [6] .
Minimum inhibitory concentrations exceeded parenteral breakpoints for at least 1 of the 9 antibiotics tested in 38 of 193 isolates (19.7%) recovered from 30 of 117 subjects (25.6%). Twenty-three participants had only 1 P aeruginosa isolate with at least 1 antibiotic MIC above a parenteral breakpoint, 6 participants had 2 isolates with at least 1 MIC above a breakpoint, and 1 participant had 3 separate isolates with at least 1 MIC above a parenteral breakpoint ( Table 1) . Only 1 isolate (Isolate B from Subject 2; Table 1 ) met Cystic Fibrosis Foundation criteria for multiple antibiotic resistance, in that it had MICs exceeding parenteral Tables 1 and 2 ). For all antibiotics tested except amikacin, proportions of EPIC isolate MICs exceeding parenteral breakpoints were lower than those reported for wildtype P aeruginosa strains (Table 2 ) [7] . Six of 193 EPIC P aeruginosa isolates (3.1%) had amikacin MICs exceeding the parenteral breakpoint of 16 mcg/mL, versus a report of only 1.5% for wild-type strains (Table 2) . There was no difference in the proportion of patients with P aeruginosa isolates exceeding at least 1 antibiotic parenteral breakpoint among those 32 patients with a past history of P aeruginosa isolation and the remaining 85 with no prior history of P aeruginosa isolation (25.0% vs 25.9%, respectively). Among patients in the current analysis, 26 (22.2%) had received antibiotic treatment between screening and baseline cultures, 10 (38.5%) of whom had at least 1 P aeruginosa isolate with MICs exceeding parenteral breakpoints for at least 1 of antibiotic tested at baseline. In contrast, of the 91 patients who did not receive antibiotics between screening and baseline culture, only 20 (22.0%) had at least 1 P aeruginosa isolate with MICs exceeding parenteral breakpoints for at least 1 of the 9 antibiotics, a difference of 16.5% (95% confidence interval: -2.2%, 36.8%).
CONCLUSIONS
Extended antibiotic administration (by any route) to individuals with CF and established infections inevitably leads to selection for less antibiotic-susceptible bacterial communities [3, 4] . Although in vitro susceptibility testing and parenteral breakpoints have not been shown to be useful predictors of antibiotic treatment response in individuals with CF [8, 9] , they can be useful measures of the cumulative antibiotic exposure experienced by an individual, as evidenced by an association between prevalence of multiple antibiotic-resistant P aeruginosa in the CF population and lung disease stage [4] . Across CF centers, an average of 9.1% of patients with P aeruginosa have multiple antibiotic-resistant isolates (range, 0% to 30%) [4] . Thus, it appears that CF clinicians in the United States have decided that the risks associated with selection for less susceptible P aeruginosa strains in CF individuals as a result of chronic antibiotic treatment are justified based on overall improvements in respiratory health and median predicted life expectancy [4, 10] .
Our results suggest that new acquisition of P aeruginosa with antibiotic susceptibilities lower than those of wildtype P aeruginosa, and specifically acquisition of multiple antibiotic-resistant P aeruginosa, is rare in children with CF despite substantial increases in the use of antibiotics over the past decades [10] . It is important to note that the EPIC protocol allowed up to 1 course of antibiotics in the time between first/recent P aeruginosa isolation at screening and baseline culture [5] and that 22.2% of patients in our analysis received antibiotics after screening and remained P aeruginosa culture-positive at baseline. For this reason, the in vitro MIC results we present here may not be entirely representative of all initial P aeruginosa isolates in the CF population.
We conclude that the majority of new P aeruginosa isolates from children with CF have antibiotic susceptibility profiles more comparable with those of wild-type strains EUCAST [7] . c Lowest antibiotic concentration tested.
than with those isolated from persons with CF and established P aeruginosa infections that have been extensively treated with antibiotics, and thus that transmission of antibiotic-resistant organisms to uninfected children with CF should not be considered a significant risk associated with chronic antibiotic treatment of patients with established P aeruginosa airway infection. In rare instances in which an initial P aeruginosa isolate was identified with elevated MICs for multiple agents of different antibiotic classes (eg, Isolate 2-B; Table 1 ), the possibility of lateral transmission from a chronically infected person with CF [11] cannot be ruled out.
